TrovaGene, Inc.(TROV)- NASDAQ
  • Fri, Feb. 26, 11:02 AM
    • Results from a recent study show Biocept's (BIOC +2%) liquid biopsy test that detects bits of tumor-related DNA in the blood agreed with tissue biopsy results 93% of the time in 74 lung cancer patients. The data were presented in a poster session at the UCSD Moores Cancer Center Industry/Academia Translational Oncology Symposium in San Diego, CA.
    • Biocept's test detects circulating tumor DNA (ctDNA) in a peripheral blood sample obtained via a routine blood draw. Tumors consistently shed bits of DNA that circulate in the blood which has potential for detecting and monitoring cancer. Because the amounts of ctDNA are very small, the clinical utility wasn't there until high powered sequencers became available, such as those made by Illumina (ILMN +1.4%). The value proposition of liquid biopsy is lower cost, greater convenience and much more patient-friendly that traditional tissue biopsy.
    • Related tickers: (TROV -4.5%)(TBIO +6.6%)(SQNM -2.1%)(CDNA +2.8%)
    | Fri, Feb. 26, 11:02 AM | 18 Comments
  • Wed, Feb. 24, 8:52 AM
    • Trovagene (NASDAQ:TROV) secures coverage of its Precision Cancer Monitoring (PCM) services by Three Rivers Provider Network. The Chula Vista, CA-based organization covers 14M people.
    • Trovagene's proprietary technology is focused on the detection of cell-free DNA (cfDNA) in urine as a potential method of managing cancer. Its value proposition is a less invasive way to monitor and detect cancer compared to tissue biopsy while being less expensive, more convenient and much more patient-friendly.
    | Wed, Feb. 24, 8:52 AM | 3 Comments
  • Mon, Feb. 22, 8:53 AM
    • Liquid biopsy firm Trovagene (NASDAQ:TROV) is up 15% premarket, albeit on only 1,200 shares, in response to its announcement that has inked a deal with healthcare benefits administrator Fortified Provider Network for in-network coverage of the company's Precision Cancer Monitoring (PCM) services. Fortified covers over 4M lives in the U.S.
    • Trovagene's proprietary technology is focused on the detection of cell-free DNA (cfDNA) in urine as a potential method of managing cancer. Its value proposition is a less invasive way to monitor and detect cancer compared to tissue biopsy while being less expensive, more convenient and much more patient-friendly.
    • Previously: Trovagene's urine-based HPV assay shows ~90% sensitivity compared to cervical samples in new study (Sept. 21, 2015)
    | Mon, Feb. 22, 8:53 AM | 2 Comments
  • Wed, Feb. 17, 7:08 AM
    • Researchers at Cal State say they have developed a liquid biopsy test for the detection of prostate cancer that is based on a single drop of saliva. They claim that it can be performed in 10 minutes and is 100% accurate.
    • Professor of oncology David Wong and prostate cancer surgeon and urologic oncologist Dr. David Samadi expect to start clinical trials by the end of this year. If successful, they say FDA clearance could happen within the next two years.
    • A tumor sheds tiny amounts of DNA that the medical community has discovered circulate in the blood and can be found in other body fluids such as urine and, apparently, saliva. This cell-free DNA (cfDNA) or circulating tumor DNA (ctDNA) can be detected and analyzed using state-of-art sequencers such as those made by Illumina (NASDAQ:ILMN). This is called "liquid biopsy" because of the sample source. A traditional biopsy is performed on a tissue sample.
    • Proponents of the liquid biopsy concept say it represents a paradigm shift in the detection and management of cancer since it has the potential for low-cost, non-invasive cancer screening and monitoring.
    • Related tickers: (NASDAQ:TROV)(NASDAQ:TBIO)(NASDAQ:SQNM)(NASDAQ:BIOC)(NASDAQ:CDNA)
    | Wed, Feb. 17, 7:08 AM | 11 Comments
  • Wed, Feb. 10, 11:35 AM
    • Illumina (ILMN +2.4%) taps board member and former Google executive Jeff Huber to lead Grail, its startup company that is developing a test to detect cancers at their earliest stages.
    • Mr. Huber's 12-year Google career involved working on advertising products, Google Maps, Google Earth and the life sciences arm of Google X.
    • Grail was started in January with more than $100M in funding from the likes of tech titans Bill Gates and Jeff Bezos. Its aim is to develop a "pan-cancer" screening test that can detect very minute levels of tumor-associated material in the blood called cell-free DNA. The process is called a liquid biopsy in light of its similar diagnostic objective to a tissue biopsy, that is, to detect very early-stage cancer. It will use Illumina's latest sequencing technology to analyze the samples. It expects to initiate a large clinical trial in 2017.
    • Illumina invested $40M in Grail's first funding round and owns more than 50% of the company.
    • Related tickers: (TROV -1.3%)(TBIO +5.4%)(SQNM +6.5%)(BIOC -0.7%)(CDNA -2.5%)
    | Wed, Feb. 10, 11:35 AM | 6 Comments
  • Mon, Feb. 1, 12:48 PM
    | Mon, Feb. 1, 12:48 PM
  • Mon, Feb. 1, 9:19 AM
    | Mon, Feb. 1, 9:19 AM | 1 Comment
  • Mon, Feb. 1, 7:14 AM
    • Trovagene (NASDAQ:TROV) establishes coverage for its liquid biopsy tests and services with FedMed, a Preferred Provider Organization (PPO) consisting of over 550,000 doctors, 4,000 hospitals and 60,000 ancillary care providers across the U.S. providing access to medical care to over 40M Americans.
    • The company's Precision Cancer Monitoring platform enables the detection of cell-free DNA in urine.
    • Shares are up 17% premarket on robust volume.
    | Mon, Feb. 1, 7:14 AM | 3 Comments
  • Fri, Jan. 22, 12:44 PM
    | Fri, Jan. 22, 12:44 PM
  • Fri, Jan. 22, 9:21 AM
    | Fri, Jan. 22, 9:21 AM | 14 Comments
  • Thu, Jan. 21, 12:45 PM
    | Thu, Jan. 21, 12:45 PM
  • Thu, Jan. 21, 8:58 AM
    • Thinly traded nano cap Trovagene (NASDAQ:TROV) is up 10% premarket on light volume in response to its announcement that it has inked an agreement with America's Choice Provider Network (ACPN) establishing insurance access to its circulating tumor (ct)DNA Precision Cancer Monitoring (PCM) tests and services. Under the terms of the agreement, Trovagene is the preferred provider, with its PCM testing services covered by over 1,700 payers in North America.
    • Chief Commercial Officer Matt Posard says that this is the first of several insurance coverage-related contracts that should be consummated this year.
    • The value proposition of ctDNA tests is the ability to conveniently and inexpensively detect and monitor cancer via urine or peripheral blood samples instead of tissue biopsies.
    | Thu, Jan. 21, 8:58 AM | 16 Comments
  • Dec. 16, 2015, 10:34 AM
    • The USPTO issues Patent No. 9,163,229 titled "Compositions, Methods and Kits for Isolating Nucleic Acids from Body Fluids Using Anion Exchange Media" to Trovagene (TROV +4.6%). The patent covers methods for the rapid separation and isolation of systemically derived circulating tumor DNA (ctDNA) and the purification of nucleic acids from urine samples using anion exchange media.
    • The new patent extends the IP portfolio covering the company's Precision Cancer Monitoring (PCM) technology.
    • The value proposition of urine-based DNA monitoring compared to tissue biopsy is that it is less invasive, more convenient, quicker, much easier to perform and less expensive.
    | Dec. 16, 2015, 10:34 AM | 18 Comments
  • Dec. 11, 2015, 12:39 PM
    • BioTime's (BTX -1.9%) board sets December 21 as the record date for the distribution of a portion of its stake in subsidiary OncoCyte to BioTime shareholders who will receive one share of OncoCyte common stock for every 20 BioTime common shares held. The distribution, expected to occur on December 31, will reduce BioTime's ownership position to ~58.6% from ~76.4%.
    • OncoCyte is not publicly traded at present, but intends to apply for listing on the NYSE MKT under the symbol "OCX" in the coming weeks. In the event that the listing is not approved, it will arrange for the trading of its shares on the OTC Bulletin Board no later than December 31.
    • OncoCyte develops "liquid biopsy" diagnostic tests that detect cancer biomarkers in blood or urine.
    • Liquid biopsy-related tickers: (TROV -4.5%)(TBIO +3.6%)(SQNM -1.5%)(BIOC -4%)(CDNA -2%)
    | Dec. 11, 2015, 12:39 PM | 9 Comments
  • Nov. 10, 2015, 12:48 PM
    | Nov. 10, 2015, 12:48 PM | 2 Comments
  • Nov. 9, 2015, 4:14 PM
    • TrovaGene (NASDAQ:TROV): Q3 EPS of -$0.23 beats by $0.04.
    • Revenue of $0.06M (flat Y/Y)
    | Nov. 9, 2015, 4:14 PM
Company Description
Trovagene, Inc. is a development stage molecular diagnostic company that focuses on the development and commercialization of a proprietary urine-based molecular diagnostic technology for use in disease detection and monitoring across a variety of medical disciplines. Its primary internal focus... More
Sector: Healthcare
Industry: Biotechnology
Country: United States